Philip M. Wade

A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant‐ineligible multiple myeloma

Elizabeth O’Donnell, Jacob P. Laubach, Andrew J. Yee et al. · British Journal of Haematology · 2018 · 162 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Small cell neuroendocrine (Oat cell) carcinoma of the breast

Philip M. Wade, Stacey E. Mills, Marc Read et al. · Cancer · 2006 · 128 citations

Medicine, Oncology, Surgery +15

A Comparison of the Audiometric Performance of Bone Anchored Hearing Aids and Air Conduction Hearing Aids

Manohar Bance, Sharon M. Abel, Blake C. Papsin et al. · Otology & Neurotology · 2002 · 44 citations

Health Professions, Audiology, Otolaryngology +17

Thy-1 antigen expression by murine high-proliferative capacity hematopoietic progenitor cells. I. Relation between sensitivity to depletion by Thy-1 antibody and stem cell generation potential.

H. Scott Boswell, Philip M. Wade, Peter J. Quesenberry · The Journal of Immunology · 1984 · 43 citations

Life Sciences, Cell Biology, Hematology +16

Updated Results of a Phase 2 Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVd-lite) in Transplant-Ineligible Multiple Myeloma

Elizabeth O’Donnell, Jacob P. Laubach, Andrew J. Yee et al. · Blood · 2019 · 23 citations

Medicine, Oncology, Pharmacotherapy +12